Drug Profile
Anti-VLA-4 monoclonal antibody R1-2
Alternative Names: Anti-alpha-4-integrin monoclonal antibody R1-2; Anti-integrin-alpha-4 monoclonal antibody R1-2Latest Information Update: 29 Oct 2001
Price :
$50
*
At a glance
- Originator Harvard Medical School; Stanford University
- Developer Biogen Idec; Harvard Medical School; Stanford University
- Class Monoclonal antibodies
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 10 Aug 2000 No-Development-Reported for Diabetes mellitus in USA (Unknown route)